Statement of the Problem: Instruments used to determine the risk of pressure ulcer development are universally applied to adult patients. These instruments do not differentiate between intensive and acute care patients. Background: Pressure ulcers contribute to negative outcomes such as increases in pain and discomfort, risk of infection, hospital length of stay and costs, and a decrease in quality of life. Appropriately identifying risk factors is paramount to implementing a targeted care plan to avoid pressure ulcer development as well as pinpointing appropriate treatments if an ulcer develops. Objective: The purpose of this nursing research study was to identify factors associated with pressure ulcer development in a medical intensive care unit. Methods: A 15-month retrospective chart review of patients with pressure ulcers in a medical intensive care unit was performed. Statistics were computed on demographics and variables of interest including: pressure ulcer stage, vasopressor infusion, oxygen requirement, comorbidities, primary diagnosis, length of stay, mortality, age, gender, weight, Braden scores, and albumin level. Results: The characteristics of 76 patients who developed pressure ulcers were evaluated. An equal number of men (n = 38) and women (n = 38) were included. Forty-seven percent had a stage II pressure ulcer. The presence of hemodynamic support with vasopressor administration
(P = .016) and the length of stay (P = .021) were noted as the most significant factors in pressure ulcer development in this study. Conclusions: Vasopressor use and length of stay are not factors that are accounted for in current pressure ulcer risk assessment instruments. The administration of vasopressor support and patient length of stay are potential contributory factors that need to be considered when assessing patients. Instruments specific to intensive care unit pressure ulcer risk stratification are warranted and should include the unique characteristics of a critically ill patient. Patients are at risk of developing pressure ulcers (PUs) in acute and intensive care units (ICUs). Pressure ulcers are recognized as a safety concern associated with hospitalization. In the United States, it is estimated that 2.5 million patients in health care facilities are treated annually for PUs. 1 According to 2006 and 2007 Medicare data, the incidence of new PUs acquired during a hospitalization is 4.5%. 2 Furthermore, those who develop a new PU tend to experience an increased length of stay (LOS), higher mortality rate, and increased likelihood of readmission. 2 Properly identifying patients at risk and intervening to prevent PU formation is an essential component of quality nursing care. Nurses need instruments that can readily identify patients at greatest risk of developing PUs so they may tailor preventive interventions to meet patients' individual needs.
Patients in the ICU are at a higher risk of skin breakdown and the development of PUs. 3, 4 These ulcers may result in numerous negative outcomes such as decrease in quality of life, increase in pain, discomfort, potential infection, and LOS, as well as increased costs. 5 Nurses must be vigilant in preventing PUs through focused identification of risk factors and detailed assessments. It is the nurse's responsibility to perform a complete skin assessment when a patient is admitted to the hospital and document any wound or PU that is present prior to admission. Clear and accurate nursing assessments and documentation help differentiate between community-acquired PUs and hospitalacquired PUs.
When a patient is admitted to the hospital, it is essential to determine and identify those at risk of developing ulcers. There are a number of different instruments that have been developed to facilitate risk stratification. The Norton, Waterlow, and Braden scales are the instruments most frequently used to determine the risk of PU development and have been universally applied to adult patients. 6 However, these scales do not necessarily differentiate between intensive and acute care patients. The most widely used instrument is the Braden scale. 7 The Braden scale is identified as the scale with the best combined sensitivity and specificity in predicting risk of PU. 8 The Braden scale was developed to promote early identification of patients who are at risk of the development of a PU. The scale is composed of 6 subscales: sensory perception, skin moisture, activity, mobility, friction and shear, and nutritional status. Scores range from 6 to 23. A lower score indicates greater risk of development of a PU. 7 In the intensive care population, the scale is 83% sensitive and 64% specific for a risk score of equal to or less than 16. 7 Patients who require intensive care may have additional risk factors that are not being captured by the Braden scale. 4 Other significant predictors of PU that have been identified in studies but are not integrated into traditional scales include factors such as age, ICU LOS, norepinephrine administration, and cardiovascular disease. 3, 9, 10 The purpose of this study was to identify factors associated with PU development in a medical ICU.
METHODS
A retrospective chart review was performed using a convenience sample of 76 medical ICU (MICU) patients who had developed PUs over a 15-month period (late 2010 to early 2012). Institutional review board approval was obtained for the study.
The MICU sampled for this study is 1 of 5 adult ICUs at an academic medical center on the east coast. The MICU is a 16-bed unit that provides comprehensive interprofessional care to critically ill patients. Full monitoring capabilities are provided. Nursing care is generally 1:1 or 1:2, depending on the acuity of the patient. Respiratory care services are provided by registered respiratory therapists 24 hours per day. Unit-based pharmacists are on site to recommend and review the medications prescribed. A certified wound and ostomy nurse is assigned to the unit on a consultative basis. Board-certified intensivists (American Board of Internal Medicine Board certified in critical care medicine or the equivalent) provide the day-to-day medical direction for the unit.
Investigators reviewed the medical records of all patients who developed a PU while in the MICU and extrapolated data into an electronic spreadsheet. Paper as well as electronic medical records were reviewed. Investigators reviewed the records in groups of no less than 2 so that variables of interest could be discussed during data extraction, and interrater reliability enhanced. The following were considered variables of interest: PU stage, hemodynamic support in the form of vasopressor infusion, oxygen requirement, number of comorbid conditions, primary diagnosis, LOS prior to PU identification, mortality, age, gender, weight, Braden scores on admission and on day of PU identification, and albumin level on admission. For purposes of this study, hemodynamic support was defined as the use of any pharmacologic agent within 24 hours of admission to the ICU to maintain hemodynamic stability. Data were explored using descriptive statistics. The data were further analyzed using # 2 and Kruskal-Wallis tests.
RESULTS
There was a significant difference based on administration of vasopressor infusion across all PU stages (P = .016).
There was also a significant difference in the number of days from admission to PU development (P = .021). However, there was not a significant difference based on gender, oxygen requirement, number of comorbidities, primary diagnosis, or mortality (Table 1) . There was not a significant difference in PU stage by age, weight, Braden scores, or albumin on admission (Table 2) . Of the 76 patients with PUs included in the study, complete data were available on 73 patients. Females represented 50% of the sample with a mean age of 61.8 years. Unstageable PUs were identified in 16% of patients and deep tissue injury in 7%, whereas 58% had a diagnosis of stage 2 or 3 PU, and 19% had stage 1 PU. The majority of the sample received vasopressor support (60%), was intubated (79%), and had more than 1 comorbidity (87%). The primary diagnosis, at 40%, was respiratory conditions followed by 27% with septic conditions. Of those patients studied, 28% had a diagnosis of PU wound on day 22 of their hospitalization or later. The mean Braden score on admission was 13.9, whereas the mean score on the day of PU identification was 13.3. The majority (55%) survived and were transitioned out of the ICU. The average weight was 87.2 kg, and the mean of albumin level at time of admission was 2.9 g/dL (Tables 1 and 2 ).
DISCUSSION
Instruments used to determine risk assessment for PU are crucial in aiding nurses and assisting in identifying patients who require additional preventive measures. Having an instrument that takes into consideration the patient population as well as the health care environment may facilitate improved care and outcomes for patients. Instruments used in the acute care setting may not be suitable for use in the ICU. 3, 4, 9 Critical care patients have additional risk factors that need to be taken into consideration. 4, 9, 10 This study's findings add to the current growing body of literature pointing to additional PU risk factors in the vulnerable ICU patient population that are not captured by current risk assessment instruments. In fact, these findings coincide with 2 previous studies that both cite vasopressor administration and LOS as statistically significant factors in PU development. 9, 10 Considering potential contributory factors such as hemodynamic support and LOS may be essential to preventing PU in critical care patients.
By accurately identifying contributory factors, preventive nursing care strategies can be implemented. Patient outcomes are enhanced by avoiding PU development during hospitalization. The Braden scale is commonly used by nursing because of its documented feasibility, reliability, and validity in the adult patient population. 7 However, this scale is intended for all patient care settings; it does not take into consideration unique attributes of the critical care patient population. Minimally, vasopressor administration and LOS should be taken into consideration when identifying the most vulnerable patients and implementing preventive PU nursing strategies.
LIMITATIONS
This study has several limitations that are acknowledged. The small study sample and the retrospective study design are both limitations. The retrospective chart review relied heavily on accurate documentation across both paper and electronic medical records leading to the potential of missing data. To promote reliability and reduce the risk of missing data, 4 primary nursing data collectors reviewed the records and obtained the variables of interest. These data collectors were familiar with the documentation on the unit and knew where to find the data points of interest in the medical records. The retrospective design also limited the analysis to only those patients for whom PU identification was clearly documented. Patients with PUs not previously captured may be missing.
Another limitation is that the data were from a single MICU over a defined period. Other specialized ICUs at the same or other institutions may have revealed varied or additional contributory factors. More studies are needed to include different critical care units in order to identify specific PU risk factors that may arise from various intensive care patient populations.
Additional vasopressor data were not collected. Information related to the length of time patients were receiving vasopressor support and specifics regarding the type of medication infused as well as dosage is lacking. This information regarding vasopressor administration could have gleaned further specifics on the factors associated with PU development in this patient population. For example, because the most common primary diagnosis in the MICU is sepsis and the Society of Critical Care Medicine guidelines recommend norepinephrine as the first-line vasopressor, 11 it is highly likely that norepinephrine was the most common vasopressor used. Norepinephrine is an !-adrenergic agonist that increases mean arterial pressure primarily through vasoconstriction. Circulation of smaller vessels such as those closest to the skin surface can be seriously compromised by vasoconstriction with norepinephrine, leading to an immediate and sustained insult and increased risk of skin breakdown. Without the collection of data about vasopressor type, the potential of norepinephrine's contribution to the PU is unknown.
CONCLUSION
This retrospective study highlights that vasopressor administration and LOS are factors associated with the development of PUs in an MICU patient population. To accurately identify a patient at risk of PU, more predictive instruments need to be developed, and preventive nursing strategies need to be individualized to prevent PU development. Additional factors need to be taken into consideration in the ICU to accurately identify patient risks and implement preventive measures to decrease PU development in this vulnerable patient population.
